Brent Snyder, head of the firm's regulatory and compliance department, brings more than 30 years of civil and criminal litigation and trial experience in both the private and public sectors. He is widely regarded as one of the world’s leading authorities on antitrust and competition enforcement in the area of antitrust cartels and related criminal violations. Brent has secured positive outcomes for leading companies and individual executives across industries in investigations by the U.S. Department of Justice (DOJ) and other antitrust enforcers, all while ensuring minimal business disruptions. 

Prior to joining the firm, Brent served as chief executive officer of the Hong Kong Competition Commission (HKCC), where he had day-to-day responsibility for all aspects of its enforcement, policy, advocacy, and administration functions. Under his leadership, the HKCC set several important litigation precedents; significantly increased the volume, variety, and complexity of its enforcement work; improved its leniency and cooperation incentives; and enhanced its competition policy and advocacy work.

Jamillia represents clients in several areas, including merger review, government investigations, and antitrust-related counseling and litigation.

Joshua advises domestic and foreign investors, funds, established companies and startups in regulatory, investigative, and enforcement matters.

Maneesha Mithal is a partner in the Washington, D.C., office of Wilson Sonsini and co-chair of the firm’s data, privacy, and cybersecurity practice. Maneesha advises clients on privacy, cybersecurity, and consumer protection matters and represents companies in regulatory investigations. She is also one of the founding members of Wilson Sonsini’s AI group.

Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.